Inmunoterapia en cáncer de vejiga - page 22

Two more molecules

•

Durvalumab

•

1108

•

Phase 1; 42 patients; PD-L1+; 31%

•

Avelumab

•

Javelin

•

Phase Ib; 44 patients; All comers; 18%; 53% OS 1-year

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,12,13,14,15,16,17,18,19,20,21 23,24,25,26,27,28,29,30,31,32,...36